Anti-CD19 chimeric antigen receptor (CAR) T cells are the first FDA-approved cellular immunotherapy, and have the potential to revolutionize the treatment of both adults and children with certain haematological malignancies. The majority of patients initially respond to treatment, but much remains to be learnt about numerous aspects of this therapy, including the durability of responses and the ability to consistently deliver bespoke cellular therapies across different geographical locations. Now, two early-phase trials with results published in the New England Journal of Medicine provide further insight into the use of CAR T cells in patients with B cell acute lymphoblastic leukaemia (B-ALL).
14.09.2018 | CAR-T-Zellen | International Research Highlight | Online-Artikel